Holen Sie sich die Stockscreener-App
82.92
0.62%
0.47
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$82.45
Offen:
$83.41
24-Stunden-Volumen:
2.51M
Relative Volume:
0.57
Marktkapitalisierung:
$48.69B
Einnahmen:
$5.88B
Nettoeinkommen (Verlust:
$1.34B
KGV:
35.35
EPS:
2.3455
Netto-Cashflow:
$577.90M
1W Leistung:
+2.65%
1M Leistung:
+7.64%
6M Leistung:
+9.66%
1J Leistung:
+22.83%
1-Tages-Spanne:
$80.24
$83.50
1-Wochen-Bereich:
$79.85
$87.09
52-Wochen-Spanne:
$64.89
$87.09
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
82.94 | 48.41B | 5.88B | 1.34B | 577.90M | 2.3455 |
|
ABT
Abbott Laboratories
|
123.52 | 214.96B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.95 | 149.24B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
358.73 | 136.23B | 24.38B | 2.94B | 4.02B | 7.6145 |
|
MDT
Medtronic Plc
|
89.85 | 116.33B | 34.20B | 4.69B | 5.30B | 3.6218 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Truist Securities Maintains Edwards Lifesciences (EW) Rating, Ra - GuruFocus
Will Edwards Lifesciences Corporation (EWL) stock test record highs in 2025 - newser.com
Bernstein Adjusts Price Target on Edwards Lifesciences to $90 From $85 - MarketScreener
Is Edwards Lifesciences Corporation (EWL) stock positioned for secular growth2025 Growth vs Value & Fast Exit and Entry Strategy Plans - newser.com
Bernstein raises Edwards Lifesciences stock price target to $90 on TAVR growth - Investing.com
Canaccord Genuity raises Edwards Lifesciences stock price target on solid Q3 - Investing.com
Machina Capital S.A.S. Makes New Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Welch & Forbes LLC - MarketBeat
Edwards Lifesciences Corporation $EW Shares Bought by Telos Capital Management Inc. - MarketBeat
South Dakota Investment Council Has $13.38 Million Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Raymond James upgrades Edwards Lifesciences stock rating to Outperform By Investing.com - Investing.com India
Can Edwards Lifesciences Corporation stock sustain institutional interestInsider Selling & Weekly High Return Stock Opportunities - newser.com
Will Edwards Lifesciences Corporation stock outperform foreign stocksJuly 2025 Highlights & Fast Entry High Yield Tips - newser.com
Raymond James upgrades Edwards Lifesciences stock rating to Outperform - Investing.com
How Edwards Lifesciences Corporation stock reacts to new regulations2025 Top Decliners & Daily Risk Controlled Trade Plans - newser.com
Strs Ohio Grows Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Amalgamated Bank Has $8.86 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation stock trend forecast2025 Market Overview & Long-Term Growth Stock Strategies - newser.com
Edwards Lifesciences Corporation (NYSE:EW) Q3 2025 Earnings Call Transcript - Insider Monkey
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Edwards Lifesciences (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $95.00 at Royal Bank Of Canada - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $95.00 - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $92.00 - MarketBeat
Mccarter Private Wealth Services LLC Reduces Position in Edwards Lifesciences Corporation $EW - MarketBeat
Lockheed Martin Investment Management Co. Has $4.34 Million Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Fisher Funds Management LTD Has $74.16 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Using data models to predict Edwards Lifesciences Corporation stock movementWeekly Trend Summary & Risk Controlled Stock Pick Alerts - newser.com
Spire Wealth Management Raises Position in Edwards Lifesciences Corporation $EW - MarketBeat
What is the fair value of Edwards Lifesciences Corporation stock nowJuly 2025 EndofMonth & Comprehensive Market Scan Insights - newser.com
Quantitative breakdown of Edwards Lifesciences Corporation recent moveMarket Performance Report & Weekly Sector Rotation Insights - newser.com
Edwards Lifesciences Topped Estimates As Demand For Heart Devices Rose - Finimize
Edwards Lifesciences Reports Strong Earnings and Growth - TipRanks
Edwards Lifesciences (NYSE:EW) Updates Q4 2025 Earnings Guidance - MarketBeat
Edwards Lifesciences (NYSE:EW) Announces Quarterly Earnings Results - MarketBeat
Edwards Lifesciences Lifts Outlook After Topping Expectations - Finimize
Edwards Lifesciences’ ALTERRA Study: A Potential Game-Changer in Heart Valve Treatment - TipRanks
Edwards Lifesciences (EW) Target Price Raised by Barclays to $99 - GuruFocus
Citigroup Raises Price Target for Edwards Lifesciences (EW) to $96 | EW Stock News - GuruFocus
Edwards Lifesciences (EW): Analyst Updates and Raised Price Targ - GuruFocus
Goldman Sachs Raises Price Target for Edwards Lifesciences (EW) to $104 | EW Stock News - GuruFocus
Canaccord Genuity Raises Edwards Lifesciences' Price Target to $84 From $81 - MarketScreener
Piper Sandler Raises Edwards Lifesciences (EW) Price Target to $95 | EW Stock News - GuruFocus
RBC Capital Raises Price Target for Edwards Lifesciences (EW) to $95.00 | EW Stock News - GuruFocus
Stifel Raises Edwards Lifesciences (EW) Price Target to $95 with Buy Rating | EW Stock News - GuruFocus
Evercore ISI Group Raises Price Target for Edwards Lifesciences (EW) | EW Stock News - GuruFocus
Leerink Partners Adjusts Price Target on Edwards Lifesciences to $88 From $84 - MarketScreener
Citigroup Adjusts Price Target on Edwards Lifesciences to $96 From $95 - MarketScreener
Stifel Adjusts Price Target on Edwards Lifesciences to $95 From $85 - MarketScreener
Wells Fargo Adjusts Price Target on Edwards Lifesciences to $95 From $88 - MarketScreener
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $92 From $88 - MarketScreener
TD Cowen Adjusts Price Target on Edwards Lifesciences to $90 From $84 - MarketScreener
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.20%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):